synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Radon at the United States Environmental Protection Agency Global Radon Map Radon at The Periodic Table of Videos (University of Nottingham) Radon and Lung Health from the American Lung Association The Geology of Radon, James K. Otton, Linda C.S. Gundersen, and R. Randall Schumann Home Buyer's and Seller's Guide to Radon An article by the International Association of Certified Home Inspectors (InterNACHI) Toxicological Profile for Radon, Draft for Public Comment, Agency for Toxic Substances and Disease Registry, September 2008
"Alzheimer's Disease Research Timeline – Alzforum". www.alzforum.org. "Alzheimer's Disease Brain Cell Atlas- brain-map.org". portal.brain-map.org. "What's the deal with Alzheimer's disease and amyloid?". For decades, scientists have concentrated on what now looks to be a blind alley. The Amyloid Mafia. Jonathan M. Gitlin, Ars Technica, Apr 15, 2026
== Career == After obtaining his PhD, Shaw spent six years working at the Centers for Disease Control and Prevention, where he was a supervisory research chemist and the chief of the radioimmunoassay laboratory. He then worked at Mercer University in Atlanta for a year as an assistant professor of pharmacy, before beginning a twelve-year stint at Smith Kline Beecham Clinical Laboratories, also in Atlanta. From 1991 until 1996, he worked at Children's Mercy Hospital in Kansas City, Missouri.
Underarm bowling incident of 1981 - Australia's Trevor Chappell became very infamous when Australia played New Zealand at the MCG on February 1, 1981, Australian captain Greg Chappell instructed the bowler (and younger brother Trevor) to bowl the last ball underarm to New Zealand batsmen Brian McKechnie to prevent him from hitting a six. After the bowl, McKechnie threw his bat onto the ground in disgust and Australia won the match. Negative post reactions then occurred after the match. Trevor Chappell was best remembered for the incident. John the bookmaker controversy – a scandal in which Australia's Mark Waugh and Shane Warne were paid in 1994–95 to provide information on pitch and weather conditions to an Indian bookmaker. The scandal came to light in 1998. South Africa cricket match fixing in 2000 which resulted in the banning from cricket of Hansie Cronje Ball tampering controversy in August 2006 - On August 20, 2006, when Pakistan toured England in the fourth test, the umpires Darrell Hair and Billy Doctrove ruled that the Pakistani team had been ball tampering and gave five penalty runs to England then offered them a new ball. After the tea break, Pakistan refused to take the field in protest at the decision. Thus, England won the match by forfeit. After the incident, the whole Pakistan team were busted of the scandal and umpire Darrell Hair was banned from umpiring in cricket.
Sources: en.wikipedia.org
William Osler Health System, Ronald McDonald House Charities, AdvaMed, Arthritis Australia, Drugs for Neglected Diseases Initiative, GISAID, Heart and Stroke Foundation of Canada, Mount Sinai Hospital (Toronto), and Truth Initiative.
It contended that the benefits were substantial and that even if bacteria became resistant, new antibiotics would soon be developed, and there was no evidence that bacterial resistance in animals impacted human health. The Netherthorpe committee's conclusions were undermined by new research even before they were published, and the committee was recalled to reconsider the issue in 1965. New studies had shown that bacteria were not only able to inherit the genes for antibiotic resistance, but they could also communicate them to each other. In 1967, a multiresistant strain of E. coli killed fifteen children in the UK. The use of antibiotics in animals for nontherapeutic use was banned there in 1971. Many other European countries soon followed. When Sweden acceded to the European Union (EU) in 1995, a total ban on antibiotic growth promoters (AGPs) had been in place there for ten years. This would be superseded by more relaxed EU rules unless Sweden could demonstrate scientific evidence in favour of a ban. Two Swedish scientists, Anders Franklin and Christina Greko, and two Danish scientists, Frank Aarestrup and Henrik Wegener, took up the fight. The odds seemed against them but this coincided with the United Kingdom BSE outbreak, which resulted in intense political pressure. In December 1996, the European Parliament's Standing Committee on Health and Welfare voted to ban the use of AGPs. The EU went further and recommended broad restrictions on the use of antibiotics. These regulations were adopted in 2019 and took effect in 2022.
On 26 September 1983, during the Cold War, the Soviet nuclear early warning system Oko reported the launch of one intercontinental ballistic missile with four more missiles behind it, from the United States. These missile attack warnings were suspected to be false alarms by Stanislav Petrov (1939–2017), an engineer of the Soviet Air Defence Forces on duty at the command center of the early-warning system. He decided to wait for corroborating evidence—of which none arrived—rather than immediately relaying the warning up the chain of command. This decision is seen as having prevented a retaliatory nuclear strike against the United States and its NATO allies, which would likely have resulted in a full-scale nuclear war. Investigation of the satellite warning system later determined that the system had indeed malfunctioned.
== Genes == In humans, the gene for the alpha subunit is located at cytogenetic location 6q14.3. It is expressed in two cell types, most notably the basophils of the anterior pituitary. The gene for the FSH beta subunit is located on chromosome 11p13, and is expressed in gonadotropes of the pituitary cells, controlled by GnRH, inhibited by inhibin, and enhanced by activin.
Prior to the development of biological therapy as a modality to treat IBD, other medications that modulate the immune system—including 5-aminosalicylates, steroids, azathioprine, and other immunosuppressants—were primarily used in treatment. Corticosteroids are effective in inducing clinical remission in patients with active IBD, but they can't be used long term due to the risk of steroid-dependence and harsh side effects. The other medications like 5-aminosalicylates and azathioprine are often used to reduce steroid use while maintaining remission, but their actual effect on the state of the disease and the need for surgery remains unknown. Patients with Crohn's disease that developed complications, including fistulae (= abnormal connections to the bowel) were treated with surgery. Patients with ulcerative colitis who do not respond to medications are still treated with colectomy (= removal of the colon). However, basic science research showed that many cytokines were elevated in both Crohn's disease and ulcerative colitis. Crohn's disease cytokines are of the type 1 (Th1) cytokines, which include TNF-α, interleukin-2, and interferon γ. Ulcerative colitis was less conclusively linked to the production of Th2 cytokines. TNF inhibiting biological therapies were initially used in IBD patients who weren't responding to conventional therapy. They proved to be very effective in some patients, shifting treatment goals from simply improving symptoms to actually changing the course of the disease by reversing mucosal inflammation and preventing long-term complications and surgery.
Sources: en.wikipedia.org
In October 2023, the EMBARK trial showed improved metastasis-free survival in high-risk, non-metastatic prostate cancer patients, leading to the FDA approval of a combination therapy in 2023. In December 2023, the company acquired Seagen, a pioneer of antibody–drug conjugates for the treatment of cancer, for $43 billion. In December 2023, the EV-302 study investigated new treatments for advanced urothelial cancer, focusing on improving care for hard-to-treat patient groups. In January 2024, omnichannel strategies were being used to provide tailored healthcare solutions for patients and professionals. In February 2024, Saama and Pfizer reached an expanded multi-year agreement to integrate AI-driven solutions across Pfizer's R&D portfolio, building on their 2020 partnership. Initially the partnership focused on automating data review processes with the Smart Data Quality (SDQ) platform — developed during Pfizer's COVID-19 vaccine trials — the partnership as of 2024 scales to streamline data review and accelerate regulatory submissions across global studies. The expanded collaboration introduces Saama's Biometrics Research and Analysis Information Network, enabling faster statistical programming, biostatistics workflows, and submission-ready outputs. In February 2024, Pfizer reported durable second-season efficacy for RSV vaccine. In June 2024, Pfizer announced a collaboration with the Abu Dhabi Department of Health to analyze real-world data on Sickle Cell Disease using AI.
The Arabia hit a tree snag and sank in the Missouri River on September 5, 1856. All 130 passengers survived, but an estimated 220 tons of cargo went down with it. Shortly thereafter, the river changed course, and the Arabia was buried underground. The cargo, destined for 16 towns on the frontier, was buried under a cornfield in Wyandotte County, Kansas, for 132 years until it was discovered in 1988 by River Salvage Inc., a group of self-proclaimed treasure hunters who began excavations. David, Greg, and Bob Hawley owned a refrigeration repair business. They partnered with Jerry Mackey, owner of Hi-Boy restaurants in Independence, Missouri, and David Lutrell from the construction industry, along with other family and friends, to form River Salvage Inc. With the permission of the land owner, they dug between November 1988 and February 1989. Although their original goal was to sell their discoveries, the historical importance of the finding quickly became apparent, and they started to plan a museum. Today, it is still owned and operated by the Hawley family, who are present there most days, often greeting visitors and answering questions.
==== Renewed clashes ==== The conflict between Houthis and Salafis in Saada Governorate was renewed in October and November. Saada government officials accused Houthi fighters of attacking a Salafi mosque in Dammaj in an attempt to drive the Sunnis out, while the Houthis accused the Salafis of using the religious institute as a staging ground for foreign Sunni fighters. The government attempted to intervene to stop the fighting. Sectarian fighting in Al Jawf Governorate lasted throughout the year. Dhamar Governorate also saw clashes between the Houthis and Salafis toward the end of the year.
In 1941, at age 40, Pauling was diagnosed with Bright's disease, a renal disease. Following the recommendations of Thomas Addis, who actively recruited Ava Helen Pauling as "nutritionist, cook, and eventually as deputy 'doctor'", Pauling believed he was able to control the disease with Addis's then-unusual low-protein salt-free diet and vitamin supplements. Thus Pauling's initial – and intensely personal – exposure to the idea of treating disease with vitamin supplements was positive. In 1965, Pauling read Niacin Therapy in Psychiatry by Abram Hoffer and theorized vitamins might have important biochemical effects unrelated to their prevention of associated deficiency diseases. In 1968, Pauling published a brief paper in Science entitled "Orthomolecular psychiatry", giving a name to the popular but controversial megavitamin therapy movement of the 1970s, and advocating that "orthomolecular therapy, the provision for the individual person of the optimum concentrations of important normal constituents of the brain, may be the preferred treatment for many mentally ill patients." Pauling coined the term "orthomolecular" to refer to the practice of varying the concentration of substances normally present in the body to prevent and treat disease. His ideas formed the basis of orthomolecular medicine, which is not generally practiced by conventional medical professionals and has been strongly criticized. In 1973, with Arthur B.
The youth set-up did not replicate the success of the late 1990s and early 2000s, though Arsenal consistently finished fourth or higher in the league between 2006 and 2011. The club earnt a reputation of functioning as a "feeder club" to bigger teams, as Wenger struggled to keep hold of his best players. He described this period as "very sensitive" because of the financial restrictions that came with the stadium move. Since the 2011–12 season, Wenger has reverted to buying proven talent, and blended experience with youth in domestic cup competitions. Arsenal have benefited from increased revenue since the Emirates move, and negotiating new sponsorship deals has allowed Wenger to make marquee signings such as Özil, Sánchez, Granit Xhaka, Alexandre Lacazette and Pierre-Emerick Aubameyang. Observing Wenger's transfer policy in 2009, Sir Alex Ferguson commented that it lacked balance and needed defensive players to solidify the Arsenal team. The players Wenger recruits have often been criticised for their character and leadership capabilities; footballer Joey Barton suggested it was because the manager discouraged them from commanding: "Sometimes you need someone to galvanise and that might be a shouter and bawler. It may not be Arsene's way, but I think they lack that." Wenger is perceived as frugal given his inactivity in transfer windows, but he has denied the stereotype: "Of course people say always to buy but you cannot make careers [and you cannot] buy every time you have an injured player. You know I have the wrong reputation. I'm not scared to spend money.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.